SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-010077
Filing Date
2022-05-16
Accepted
2022-05-16 16:12:13
Documents
59
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q alna-20220331.htm   iXBRL 10-Q 2239702
2 EX-3.1 alna-ex3_1.htm EX-3.1 665002
3 EX-3.2 alna-ex3_2.htm EX-3.2 217539
4 EX-31.1 alna-ex31_1.htm EX-31.1 14409
5 EX-31.2 alna-ex31_2.htm EX-31.2 14397
6 EX-32.1 alna-ex32_1.htm EX-32.1 14520
  Complete submission text file 0000950170-22-010077.txt   7954745

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT alna-20220331_cal.xml EX-101.CAL 33477
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT alna-20220331_def.xml EX-101.DEF 195376
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT alna-20220331_pre.xml EX-101.PRE 299432
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT alna-20220331_lab.xml EX-101.LAB 386831
11 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT alna-20220331.xsd EX-101.SCH 41312
53 EXTRACTED XBRL INSTANCE DOCUMENT alna-20220331_htm.xml XML 1007504
Mailing Address ONE NEWTON EXECUTIVE PARK SUITE 202 NEWTON MA 02462
Business Address ONE NEWTON EXECUTIVE PARK SUITE 202 NEWTON MA 02462 617-467-4577
Allena Pharmaceuticals, Inc. (Filer) CIK: 0001624658 (see all company filings)

IRS No.: 452729920 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38268 | Film No.: 22929102
SIC: 2836 Biological Products, (No Diagnostic Substances)